Should a child’s life depend on their parent’s ability to moonlight as a VC and biotech CEO?

The science of genetic medicine has officially entered the era of software-based healing.

Yet our healthcare system is still running on 20th-century industrial hardware.

Recent breakthroughs, like the AMT130 gene therapy for Huntington’s Disease — which showed a 75% slowing of disease progression — prove that we can now silence toxic proteins at their source. But for some 400 million people living with rare diseases, these “miracles” are statistically impossible, under current economic models.

Take Terry Pirovolakis. He raised $4.5 million to build a bespoke biotech company to save his son from SPG50. While Terry’s story is a triumph of the human spirit, it exposes a systemic failure: the parental competence lottery.

Should a child’s life depend on their parent’s ability to moonlight as a venture capitalist and biotech CEO?

Up till today, 95% of rare diseases have no treatment. Not because the science is missing, but because the “math” of traditional drug development doesn’t work for — let’s say — 80 patients, total.

Not just more money is what we need; we need a fundamental shift from treating rare diseases as unique biological puzzles to treating them as standardized genetic coding errors.

Genetic coding errors, you say?

• Huntington’s Disease Breakthrough: the therapy uses a harmless virus to deliver instructions that reduce the production of toxic Huntington proteins in the brain.
• The Struggle for SPG50: a rare condition with only ~80 known cases worldwide. Because it was not commercially viable for Big Pharma, Terry Pirovolakis raised $4.5 million and hired a team to develop bespoke gene therapy.
• Systemic Barriers: The primary barriers are the relatively high costs — often $1M to $5M per rare disease patient — and the lack of interest from Big Pharma, due to low profit potential.
• Potential solution: advocate for newborn genetic screening, to enable treatment within days of birth. Catching rare diseases early perhaps shifts the outcome from “management” to a “near-cure”.

1. Parent-led biotech is not a viable model for some 10,000 known rare diseases

Terry’s success required him to be an extrovert, raise millions, and possess a “never give up” attitude. This creates a wealth/capability gap: what happens to the children of parents who aren’t millionaire fundraisers or PhD-level networkers?

Such a model risks turning medicine into a lottery of parental competence.

2. “Copy/Paste” regulatory framework

Pharmaceutical companies aren’t necessarily being “greedy”; the regulatory hurdle for a drug for 80 people is nearly the same as for 80 million. If we demand “standard” clinical trials (impractical/unethical for these cases) the cost per patient becomes mathematically impossible for any private or public entity to sustain.

We shouldn’t be asking Big Pharma to change their math; we should be asking regulators to create a Tiered Safety Protocol for rare diseases that allows for faster, cheaper, and more experimental pathways than a traditional Phase III trial.

3. Psychological and ethical nightmare of rare disease treatment

Screening without accessible treatment is a psychological and ethical nightmare. If we identify 10,000 diseases at birth but only have therapies for 500 we are handing parents a “death clock” with no solution.

Must screening follow, not precede, the creation of scalable therapy platforms?

4. Platform over Pill

Instead of focusing on “The Huntington’s Treatment” or “The SPG50 Treatment,” we should be prioritizing Platform Technologies. We need to stop treating each rare disease as a unique bio puzzle and start treating them as gene coding errors.

If the delivery mechanism (the virus/lipid nanoparticle) and the regulatory framework were standardized, the “genetic instructions” could be swapped out like software. But the current regulatory system still treats every “copy/paste” as a brand-new, multi-billion-dollar drug.

Science is moving into the 21st century (software-based medicine, gene editing), but the economics and regulations are stuck in the 20th century (industrial-scale manufacturing). Until we bridge that gap, the “1 in 10” folks will remain underserved.

Biology as a Tech Stack

Stress-Testing the Software-based Medicine Logic

While the “software” analogy is powerful, we need to be intellectually honest about where it breaks down.

1. The Legacy Code Problem 

Biology is not as clean as Python or C++. Human DNA is full of “spaghetti code” — non-coding regions, epigenetic markers, and ancient viral remnants. We can’t just “patch” a gene without considering the systemic dependencies. A “bug” in genetic code doesn’t just crash an app; it can trigger a cytokine storm or oncogenesis (cancer).

2. Human Body’s Natural Firewall

In tech, you can install an app on any phone. In biology, many patients have neutralizing antibodies — the body’s natural firewall. If a patient has been exposed to the “standard” AAV virus (the hardware) before, their immune system will delete the “app” before it can ever run. A living-breathing “Universal Platform” isn’t truly universal until we solve for immune evasion.

3. The Vendor Lock-in Risk 

If we move to a platform model, who owns the “OS”? If one or two companies own the most effective delivery vectors, they become the “Microsoft” of life itself. We risk trading the current “lack of interest” for a future of monopolistic gatekeeping, where the price of the delivery hardware remains artificially high even if the code is cheap to write.

The API for Human Life?

We could stop treating rare disease patients like a unique biological mystery and start treating them like a user with a corrupted file. The path forward is Standardized Vectors (APIs). If the US Food and Drug Administration can approve the ‘delivery truck’ once, we should be able to swap the ‘cargo’ (the gene) with minimal friction.

Until we decouple the delivery hardware from the genetic software, the price of life will remain ‘commercially unviable’ for the 1 in 10 folks among us.

Demand a Regulatory Revolution

The bespoke model of medicine is a noble stopgap, but it isn’t a rare disease strategy. To move from managing symptoms to curing 10,000 rare diseases, we need to stop asking for biotech charity and start demanding policy innovation.

Are you ready to bridge the gap between 21st-century science and 20th-century regulation?

• Co-develop the advocacy for a Tiered Safety Protocol that allows ultra-rare treatments to bypass traditional Phase III hurdles.

• Share this post to further challenge the narrative that rare disease research isn’t commercially viable.

[Join the Deeptech Revolution]